Optimal dose for the efficacy of asenapine in patients with schizophrenia: Real-world data.

ABSTRACT:

Aims

A meta-analysis of short-term studies revealed no significant differences between the doses of asenapine, 10 and 20 mg/day, in the acute treatment of schizophrenia. However, it should be noted that many patients from clinical practice were excluded, and the dose-response to asenapine in a real-world setting is still unclear. Additionally, the dose-response in the maintenance phase is not clear. This study aimed to evaluate the differences in the efficacy of different asenapine doses in patients with maintenance phase of schizophrenia in a real-world setting.

Methods

This study conducted post-marketing surveillance of asenapine in clinical settings in Japan. It followed patients diagnosed with schizophrenia who received asenapine for the first time for a maximum of 52 we

SUBMITTER: Takekita Y 

PROVIDER: S-EPMC10932759 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature